Weiping Yu1, Jonathan McConathy2, Jeffrey J Olson3, Mark M Goodman4. 1. Department of Radiology and Imaging Sciences, School of Medicine, Emory University, Atlanta, GA. Electronic address: wyu2@emory.edu. 2. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, GA. 3. Department of Neurosurgery, School of Medicine, Emory University, Atlanta, GA. 4. Department of Radiology and Imaging Sciences, School of Medicine, Emory University, Atlanta, GA.
Abstract
INTRODUCTION: Amino acid based radiotracers target tumor cells through increased uptake by membrane-associated amino acid transport (AAT) systems. In the present study, four structurally related non-natural (18)F-labeled amino acids, (R)- and (S)-[(18)F]FAMP 1 and (R)- and (S)-[(18)F]MeFAMP 2 have been prepared and evaluated in vitro and in vivo for their potential utility in brain and systemic tumor imaging based upon primarily system A transport with positron emission tomography (PET). METHODS: The transport of enantiomers of [(18)F]FAMP 1 and [(18)F]MeFAMP 2 was measured through in vitro uptake assays in human derived cancer cells including A549 (lung), DU145 (prostate), SKOV3 (ovary), MDA MB468 (breast) and U87 (brain) in the presence and absence of amino acid transporter inhibitors. The in vivo biodistribution of these tracers was evaluated using tumor mice xenografts at 15, 30, 60 and 120 min post injection. RESULTS: All four tracers showed moderate to high levels of uptake (1-9%ID/5×10(5) cells) by the cancer cell lines tested in vitro. AAT cell inhibition assays demonstrated that (R)-[(18)F]1 and (S)-[(18)F]1 entered these tumor cells via mixed AATs, likely but not limited to system A and system L. In contrast, (R)-[(18)F]2 and (S)-[(18)F]2 showed high selectivity for system A AAT. Similar to the results of in vitro cell studies, the tumor uptake of all four tracers was good to high and persisted over the 2 hours time course of in vivo studies. The accumulation of these tracers was higher in tumor than most normal tissues including blood, brain, muscle, bone, heart, and lung, and the tracers with the highest in vitro selectivity for system A AAT generally demonstrated the best tumor imaging properties. Higher uptake of these tracers was observed in the pancreas, kidney and spleen compared to tumors. CONCLUSIONS: These preclinical studies demonstrate good imaging properties in a wide range of tumors for all four amino acids evaluated with (R)-[(18)F]2 having the highest selectivity for system A AAT.
INTRODUCTION: Amino acid based radiotracers target tumor cells through increased uptake by membrane-associated amino acid transport (AAT) systems. In the present study, four structurally related non-natural (18)F-labeled amino acids, (R)- and(S)-[(18)F]FAMP 1 and (R)- and(S)-[(18)F]MeFAMP 2 have been prepared and evaluated in vitro and in vivo for their potential utility in brain and systemic tumor imaging based upon primarily system A transport with positron emission tomography (PET). METHODS: The transport of enantiomers of [(18)F]FAMP 1 and [(18)F]MeFAMP 2 was measured through in vitro uptake assays in human derived cancer cells including A549 (lung), DU145 (prostate), SKOV3 (ovary), MDA MB468 (breast) and U87 (brain) in the presence and absence of amino acid transporter inhibitors. The in vivo biodistribution of these tracers was evaluated using tumormice xenografts at 15, 30, 60 and 120 min post injection. RESULTS: All four tracers showed moderate to high levels of uptake (1-9%ID/5×10(5) cells) by the cancer cell lines tested in vitro. AAT cell inhibition assays demonstrated that (R)-[(18)F]1 and (S)-[(18)F]1 entered these tumor cells via mixed AATs, likely but not limited to system A and system L. In contrast, (R)-[(18)F]2 and (S)-[(18)F]2 showed high selectivity for system A AAT. Similar to the results of in vitro cell studies, the tumor uptake of all four tracers was good to high and persisted over the 2 hours time course of in vivo studies. The accumulation of these tracers was higher in tumor than most normal tissues including blood, brain, muscle, bone, heart, and lung, and the tracers with the highest in vitro selectivity for system A AAT generally demonstrated the best tumor imaging properties. Higher uptake of these tracers was observed in the pancreas, kidney and spleen compared to tumors. CONCLUSIONS: These preclinical studies demonstrate good imaging properties in a wide range of tumors for all four amino acids evaluated with (R)-[(18)F]2 having the highest selectivity for system A AAT.
Authors: M Schwarzbach; F Willeke; A Dimitrakopoulou-Strauss; L G Strauss; Y M Zhang; G Mechtersheimer; U Hinz; T Lehnert; C Herfarth Journal: Anticancer Res Date: 1999 Mar-Apr Impact factor: 2.480
Authors: T M Shoup; J Olson; J M Hoffman; J Votaw; D Eshima; L Eshima; V M Camp; M Stabin; D Votaw; M M Goodman Journal: J Nucl Med Date: 1999-02 Impact factor: 10.057
Authors: Jennifer L Burkemper; Chaofeng Huang; Aixiao Li; Liya Yuan; Keith Rich; Jonathan McConathy; Suzanne E Lapi Journal: J Med Chem Date: 2015-10-20 Impact factor: 7.446
Authors: Thomas C Pickel; Gouthami Pashikanti; Ronald J Voll; Weiping Yu; Zhaobin Zhang; Jonathon A Nye; John Bacsa; Jeffrey J Olson; Lanny S Liebeskind; Mark M Goodman Journal: ACS Pharmacol Transl Sci Date: 2021-04-05